Safety of agalsidase alfa in patients with fabry disease under 7 years

Acta Paediatrica, International Journal of Paediatrics

Volumn 100, Issue 4, 2011, Pages 605-611

  Ramaswami, Uma ^a   Parini, R ^b   Kampmann, C ^c   Beck, M ^c  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b SAN GERARDO HOSPITAL   (Italy)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Agalsidase alfa; Children; Enzyme replacement therapy; Fabry disease; Safety

Indexed keywords

AGALSIDASE ALFA; IMMUNOGLOBULIN G ANTIBODY;

ABDOMINAL PAIN; ANTIBODY BLOOD LEVEL; ARTICLE; BRONCHITIS; CHILD; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DENTAL CARIES; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ENTERITIS; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FLATULENCE; FLUSHING; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE MASS; HOME CARE; HUMAN; INFECTION; MALE; MEDICAL RECORD REVIEW; NAUSEA; NORMAL VALUE; OTITIS MEDIA; OUTCOME ASSESSMENT; PAIN; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; RIGOR; SIDE EFFECT; TREATMENT DURATION; VITAL SIGN; VOMITING;

ALPHA-GALACTOSIDASE; CHILD; CHILD, PRESCHOOL; DRUG ERUPTIONS; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOGLOBULIN G; INFUSIONS, INTRAVENOUS; ISOENZYMES; MALE; RETROSPECTIVE STUDIES; SAFETY; TREATMENT OUTCOME;

EID: 79952748856     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2010.02101.x     Document Type: Article

References (30)

1. Schiffmann R. Fabry disease. Pharmacol Ther 2009; 122: 65-77.
2. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249-54. (Pubitemid 29058114)
3. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006; 79: 31-40. (Pubitemid 43927374)
4. Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006; 95: 86-92. (Pubitemid 43041735)
5. Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I, et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 2003; 162: 767-72. (Pubitemid 37410024)
6. Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, et al. Pediatric Fabry disease. Pediatrics 2005; 115: e344-55.
7. Pintos-Morell G, Beck M. Fabry disease in children and the effects of enzyme replacement treatment. Eur J Pediatr 2009; 168: 1355-63.
8. Lidove O, West ML, Pintos-Morell G, Reisin K, Nicholls K, Figuera LE, et al. Effects of enzyme replacement therapy in Fabry disease - a comprehensive review of the medical literature. Genet Med 2010; 12: 713-20.
9. Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 2007; 96: 122-7.
10. Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006; 118: 924-32. (Pubitemid 46091613)
11. Schiffmann R, Martin RA, Reimschisel T, Johnson K, Castaneda V, Lien YH, et al. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 2010; 156: 832-7.
12. Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 2008; 152: 563-70.
13. West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009; 20: 1132-9.
14. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007; 18: 1547-57. (Pubitemid 46717522)
15. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009; 119: 524-9.
16. Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743-9. (Pubitemid 32525371)
17. Counahan R, Chantler C, Ghazali S, Kirkwood B, Rose F, Barratt TM. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 1976; 51: 875-8.
18. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-67.
19. Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension 1987; 9: II19-26.
20. Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr 2009; 22: 709-14.
21. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006; 21: 345-54. (Pubitemid 43159987)
22. Lubanda JC, Anijalg E, Bzduch V, Thurberg BL, Benichou B, Tylki-Szymanska A. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med 2009; 11: 256-64.
23. Tondel C, Ramaswami U, Aakre KM, Wijburg F, Bouwman M, Svarstad E. Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. Nephrol Dial Transplant 2010; 25: 1507-13.
24. Tondel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 2008; 51: 767-76. (Pubitemid 351626251)
25. Ramaswami U, Najafian B, Schieppati A, Mauer M, Bichet DG. Assessment of renal pathology and dysfunction in children with Fabry disease. Clin J Am Soc Nephrol 2010; 5: 365-70.
26. Cousins A, Lee P, Rorman D, Raas-Rothschild A, Banikazemi M, Waldek S, et al. Home-based infusion therapy for patients with Fabry disease. Br J Nurs 2008; 17: 653-7.
27. Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs 2006; 15: 330-3.
28. Parini R, Pozzi K, Di MS, Furlan F, Rigoldi M. Intravenous enzyme replacement therapy: hospital vs home. Br J Nurs 2010; 19: 892-8.
29. Allen LE, Cosgrave EM, Kersey JP, Ramaswami U. Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity. Br J Ophthalmol 2010; 94: 1602-5.
30. Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006; 8: 539-48. (Pubitemid 44402030)